Brief: Sana Biotechnology On Sept 12, Spokesperson Said Expects To File An Ind Filing For Sc291 Product Candidate In Autoimmune Diseases In Q4 2023
13/09/2023 11:34
Sana Biotechnology Inc SANA.O :
* SANA BIOTECHNOLOGY: ON SEPT 12, SPOKESPERSON SAID EXPECTS
TO
FILE AN IND FILING FOR SC291 PRODUCT CANDIDATE IN AUTOIMMUNE
DISEASES IN Q4 2023
* SANA BIOTECHNOLOGY INC: EXPECTS CLINICAL DATA FROM
EVALUATION OF
SC291 IN AUTOIMMUNE DISEASES IN 2024
Source text for Eikon: ID:
Further company coverage: SANA.O
Recent news on Sana Biotechnology
See all newsSana Biotechnology Inc reports results for the quarter ended June 30 - Earnings Summary
Sana Biotechnology Q2 adjusted loss narrows, beats estimates
Brief: Sana Biotechnology Q2 Adjusted EPS USD -0.13 Vs. IBES Estimate USD -0.15
Sana Biotechnology posts Q1 adjusted loss narrower than expected, extends cash runway
Brief: Sana Biotechnology Q1 Adjusted EPS USD -0.14 Vs. IBES Estimate USD -0.17